StreetInsider.com News Articles

Form 6-K Quantum Biopharma Ltd. For: Oct 08

Thu, 08 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261008/27163986.html

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quant

Thu, 08 Oct 2026 08:00:00 -0400

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has agreed to consolidate both the Company’s direct action and a class action led by an individual investor alleging market manipulation. In addition, the court appointed experienced law firm Grant & Eisenhofer P.A. (“Grant & Eisenhofer”) as lead counsel in the class action. According to Grant & Eisenhofer, the

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quant

Thu, 08 Oct 2026 08:00:00 -0400

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quant

Thu, 08 Oct 2026 08:00:00 -0400

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quant

Thu, 08 Oct 2026 08:00:00 -0400

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quant

Thu, 08 Oct 2026 08:00:00 -0400

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quant

Thu, 08 Oct 2026 08:00:00 -0400

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum B

Thu, 08 Oct 2026 08:00:00 -0400

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum B

Thu, 08 Oct 2026 08:00:00 -0400

Form 6-K Quantum Biopharma Ltd. For: Oct 06

Tue, 06 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261006/27151354.html

Quantum BioPharma signs Thermo Fisher deal for MS Phase 2 trial

Tue, 06 Oct 2026 06:00:21 -0400

Quantum BioPharma Ltd. (NASDAQ: QNTM) has entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement a Phase 2 clinical trial of its investigational compound Lucid-21-302, known as Lucid-MS, for multiple sclerosis.

The agreement initiates formal study start-up activities following clearance from the U.S. Food and Drug Administration to proceed with the trial. Thermo Fisher's PPD Clinical Research Business will support study start-up activities and related clinical research services.

The Phase 2 trial is designed as a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Tue, 06 Oct 2026 06:00:00 -0400

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement Quantum’s Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”).

The execution of the contract represents an important milestone in the clinical development of Lucid-MS

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Tue, 06 Oct 2026 06:00:00 -0400

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy

The execution of the contract represents an important milestone in the clinical development of Lucid-MS

Form SCHEDULE 13G/A Quantum Biopharma Ltd. Filed by: AdvisorShares Trust

Mon, 05 Oct 2026 09:40:00 -0400

si-local-file:///var/storage/secattach/20261005/27146866.html

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Wed, 30 Sep 2026 08:00:00 -0400

AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Anthony Durkacz, Co-Founder and Executive Co-Chair of

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Wed, 30 Sep 2026 08:00:00 -0400

Quantum BioPharma licensee Unbuzzd names new CEO, eyes stock listing

Thu, 24 Sep 2026 08:01:36 -0400

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has appointed Michael "Zappy" Zapolin as chief executive officer, according to a press release. Zapolin's mandate includes securing financing, listing Unbuzzd on a stock exchange, and executing a commercial marketing and product rollout in the United States.

Zapolin began his career at Bear Stearns before becoming an early internet entrepreneur associated with domains including Beer.com and CreditCards.com. He later co-founded KetaMD, an at-home ketamine telemedicine company acquired by Braxia Scientific in 2022. He is a graduate of Boston University and Harvard Business School's Owner/President Management Program.

Richard Buzbuzian, the previous

Form 6-K Quantum Biopharma Ltd. For: Sep 24

Thu, 24 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260924/27099081.html

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Thu, 24 Sep 2026 08:00:00 -0400

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee – Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone in the Company. His mandate includes financing and listing Unbuzzd on a stock exchange and then executing a nationwide commercial marketing and product rollout in the United States.

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Thu, 24 Sep 2026 08:00:00 -0400

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Thu, 24 Sep 2026 08:00:00 -0400

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Thu, 24 Sep 2026 08:00:00 -0400

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Thu, 24 Sep 2026 08:00:00 -0400

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Thu, 24 Sep 2026 08:00:00 -0400

Form 6-K Quantum Biopharma Ltd. For: Sep 17

Thu, 17 Sep 2026 15:13:00 -0400

si-local-file:///var/storage/secattach/20260917/27075463.html